Evelo Biosciences

$2.95 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Evelo Biosciences

Evelo Biosciences, Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis, atopic dermatitis, rheumatoid arthritis, and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases, such as colorectal cancer, renal cell carcinoma, and melanoma among others.

Stock Analysis

last close $2.71
1-mo return 15.8%
3-mo return 19.4%
avg daily vol. 79.9T
52-week high 12.74
52-week low 1.42
market cap. $303M
forward pe -
annual div. -
roe -349%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 74.8%
baraka

Subscribe now for daily local and international financial news

Subscribe